drugset / Trial / NCT02914548

Study of OPA-15406 Ointment in Patients With Atopic Dermatitis

NCT02914548

Phase 2 Completed 200 enrolled Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.

Timeline

Start
2016-09
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Difamilast Small molecule 0.3 %
Subject Difamilast Small molecule 1 %

Indications